Drug Database
AD

Adenosine (adenosine, Sanofi / Adenoscan inj / Adenosine, Pfizer)

✓ Approved

Astellas Pharma · 小分子 · 小分子

什么是 Adenosine?

Adenosine 是一种小分子,由Astellas Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名adenosine, Sanofi, Adenoscan inj, Adenosine, Pfizer
公司Astellas Pharma
药物类别小分子, 影像药物
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

Adenosine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersArteriosclerosis coronary artery✓ Approved
Hepatobiliary disordersHepatic ischaemia✓ Approved

相关研究文献

PubMedNature communications2026-11-19

Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice.

Singhal Rashi R, Zhang Nina W NW, Lee Zheng Hong ZH, Bell Hannah N HN et al.

As solid tumors progress, the tumor microenvironment becomes increasingly immunosuppressive, impairing cytotoxic T-cell activity and limiting the efficacy of immune checkpoint blockade. However, the mechanistic drivers of this immunosuppression remain poorly understood. Here, we identify a tumor-derived lipid-neutrophil-adenosine axis as a critical regulator of immune suppression in advanced colorectal cancer (CRC). We show that fatty acids enriched in tumor interstitial fluid reprogram neutrophils toward an immunosuppressive phenotype through PPARα activation, upregulation of CD39 and CD73, and adenosine generation, ultimately leading to T-cell suppression. AB928, a dual A2aR/A2bR adenosine receptor antagonist currently in clinical trials, restores T-cell proliferation, effector function, and tumor-killing capacity in vitro and in vivo. Importantly, AB928 synergizes with anti-PD-1 therapy to enhance survival in an immunotherapy-resistant autochthonous model of metastatic CRC. Thus, our findings define a metabolic immune evasion mechanism in the microenvironment and provide a rationale for targeting neutrophil-derived adenosine signaling to improve immunotherapy responses in CRC.

PMID 43052331
阅读全文 →
PubMedBrain and behavior2026-11-19

Neuroprotective Mechanisms of Electroacupuncture at Baihui (GV20) in Experimental Ischemic Stroke: A Narrative Review.

Zhang Shuo S, Cui Yang Y, Zhou Xinyu X, Wang Delong D et al.

Ischemic stroke is a major cause of death and disability, and reperfusion therapy has a narrow time window and may cause further injury after recanalization. Baihui (GV20) is the acupoint used most often in experimental studies of acupuncture for stroke, and electroacupuncture (EA) at GV20, applied alone or combined with other acupoints, has been tested in a large body of animal work. Taking GV20 as its organizing focus, this review systematically summarizes the mechanisms by which GV20-based EA protects against ischemic stroke in animal models. GV20-based EA has been reported to reduce neuroinflammation through the α7 nicotinic acetylcholine receptor-high-mobility group box 1 pathway, nuclear factor-κB and inflammasome signaling, and glial responses; to prevent apoptosis, pyroptosis, and ferroptosis and engage adenosine A1 receptor signaling; to preserve mitochondrial dynamics, energy metabolism, and redox balance; to protect the blood-brain barrier and promote cerebral perfusion and angiogenesis; and to enhance neurotrophic signaling, synaptic plasticity, and white matter repair. GV20 alone has been studied mainly as preconditioning, and GV20-based combinations have been applied primarily after ischemia; the effects on hypoxia-inducible factor-1α, autophagy, and microglial polarization vary with the timing of EA and assessment. Because these findings derive largely from young, healthy rodents and most mechanistic results are based on changes in expression, they do not yet support direct clinical application; future studies should compare GV20 alone with GV20-based combinations under the same conditions and validate key mechanisms with causal designs in clinically relevant models.

PMID 43053462
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Cryo-EM Structure of a Monomeric Safracin B Nonribosomal Peptide Synthetase Enabled by an MbtH-like Protein and Covalent Probe Trapping.

Haraguchi Naoto N, Takahashi Kanami K, Matsuda Kana K, Honda Kiichi K et al.

Nonribosomal peptide synthetases (NRPSs) assemble structurally complex natural products but remain challenging targets for high-resolution structural analysis because of their conformational heterogeneity and dynamic catalytic cycles. SacC/SfmC is an unusual single-module NRPS that diverges from canonical peptide-forming assembly lines and instead catalyzes two sequential Pictet-Spengler reactions between a tyrosine-derived unit and a peptidyl aldehyde generated through thioester reduction. This cascade forms two C-C bonds, stereoselectively installs multiple stereogenic centers, and constructs the pentacyclic scaffold of bis-tetrahydroisoquinoline antitumor alkaloids including safracin B and the clinically important ecteinascidins. Here, we establish a state-resolved cryo-electron microscopy (cryo-EM) strategy for structural interrogation of the monomeric noncanonical NRPS SacC and report its thioesterification-state structure at 2.76 Å resolution. Stabilization of this transient catalytic state was achieved by combining the cognate MbtH-like partner protein with a tailored covalent adenosine vinylsulfonamide probe that mimics the aminoacyl-adenylate intermediate and traps the phosphopantetheine-tethered species within the adenylation domain. The structure directly visualizes a carrier protein-tethered intermediate and reveals the spatial organization of the Pictet-Spengler, adenylation, peptidyl carrier protein, and reduction domains, providing the first structural view of a Pictet-Spengler cyclization domain embedded within an NRPS assembly line. In parallel, nonreducible ester probes corresponding to downstream PCP-bound intermediates were developed to enable structural interrogation of additional catalytic states along the SacC reaction trajectory. These results demonstrate that rational chemical probe design enables state-resolved cryo-EM analysis of highly dynamic, single-module NRPSs and establishes a general strategy for capturing catalytic trajectories and enabling the engineering of noncanonical NRPS reactivity.

PMID 43053361
阅读全文 →
PubMedCell biochemistry and function2026-11-18

Palmitate Drives Mitochondrial and Endoplasmic Reticulum Stress Through Disruption of Adenosine Signaling.

Dawson Shantiece S, Batan Sonia S, Adams Nina N, Bombin Sergei S et al.

Metabolic disorders associated with elevated saturated fatty acids are linked to chronic inflammatory diseases, including periodontitis, yet the mechanisms connecting lipotoxic stress to gingival inflammation remain unclear. This study investigated how palmitate-induced metabolic stress affects purinergic signaling, mitochondrial function, and endoplasmic reticulum (ER) stress in murine gingival fibroblasts (mGF), and whether adenosine modulates these effects. mGF were treated with bovine serum albumin (BSA) control, palmitate, interleukin (IL)-1β, or palmitate plus IL-1β, followed by bulk Ribonucleic acid (RNA) sequencing, real-time extracellular flux analysis, biochemical assays, and transmission electron microscopy. Palmitate altered the expression of multiple components of purinergic adenosine signaling, including cluster of differentiation CD73 (Nt5e), CD39 (Entpd1), adenosine kinase(Adk), adenosine deaminase (Ada), and adenosine receptors. Concurrently, palmitate and IL-1β together enhanced the expression of inflammatory mediators such as C-X-C motif chemokine ligand (Cxcl)1, Cxcl2, Cxcl5, Ccl2, and Il6. Gene ontology analysis demonstrated enrichment of pathways related to innate immune activation, oxidative stress, mitochondrial dysfunction, ER stress, and purine metabolism. Palmitate also induced intracellular lipid accumulation and mitochondrial dysfunction, evidenced by reduced Nicotinamide Adenine Dinucleotide (NAD) + /NADH ratio, increased mitochondrial reactive oxygen species (ROS), elevated protein oxidation, and increased proton leak despite enhanced electron transport chain protein expression. Ultrastructural analyses revealed swollen mitochondria, ER expansion, and increased ER-mitochondrial associations. Mechanistically, palmitate activated the protein kinase R-like ER kinase (PERK)- eukaryotic initiation factor 2 (eIF2)α- activating transcription factor 4 (ATF4) ER stress pathway, increasing phosphorylation of PERK and eIF2α and elevating ATF4 expression. Extracellular adenosine attenuated mitochondrial ROS accumulation, decreased PERK and ATF4 activation, improved mitochondrial respiration, and preserved ER and mitochondrial ultrastructure. Palmitate alters adenosine signaling while promoting mitochondrial dysfunction, oxidative stress, and PERK-mediated ER stress in gingival fibroblasts. Adenosine signaling protects against lipotoxic-induced ER stress and mitochondrial dysfunction, supporting the adenosine receptor axis as a potential regulatory pathway in metabolically driven periodontal inflammation.

PMID 43046709
阅读全文 →
PubMedInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026-11-18

Fuzuloparib plus apatinib maintenance in patients with platinum-sensitive recurrent ovarian cancer previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance (FLASH): an exploratory phase II trial.

Lv Mengmeng M, Lu Jin J, Ma Xuejiao X, Shen Yang Y et al.

Fuzuloparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, has demonstrated survival benefits as maintenance therapy in poly(adenosine diphosphate-ribose) polymerase inhibitor-naïve patients with platinum-sensitive recurrent ovarian cancer. This study evaluated the efficacy and safety of fuzuloparib combined with apatinib in patients with platinum-sensitive recurrent ovarian cancer who were previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance. This single-arm, exploratory phase II trial enrolled adults with ovarian cancer who had received first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance and had responded to recent platinum-based chemotherapy. Participants received oral fuzuloparib (100 mg twice daily) plus apatinib (250 mg once daily) until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was progression-free survival. Between April 2022 and January 2024, 28 patients (median age: 54.5 years) were enrolled. The median time since the most recent poly(adenosine diphosphate-ribose) polymerase inhibitor treatment was 5.4 months (interquartile range; 4.4-6.7). Bevacizumab was used in the most recent chemotherapy regimen in 60.7% of patients, and 85.7% achieved a partial response to the recent chemotherapy. With a median follow-up of 9.9 months, the median progression-free survival was 4.86 months (95% confidence interval 3.38 to 9.40). The median progression-free survival was 5.29 months (95% confidence interval 1.05 to 9.40) in patients who received bevacizumab and 4.53 months (95% confidence interval 2.4 to not reached) in those who did not. The median overall survival was 15.87 months (95% confidence interval 15.54 to not reached), although this estimate remained immature because of the limited number of observed events. Grade 3 or 4 adverse events occurred in 32.1% of patients, most commonly decreased platelet count (14.3%) and anemia (10.7%). No cases of myelodysplastic syndrome, acute myeloid leukemia, or treatment-related deaths were observed. This study is the first, to our knowledge, to evaluate dual oral therapy with fuzuloparib and apatinib in patients with platinum-sensitive recurrent ovarian cancer who were previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance. Preliminary findings suggest anti-tumor activity with manageable toxicity, warranting further investigation. chictr.org.cn: ChiCTR2200059352.

PMID 43052119
阅读全文 →
PubMedACS pharmacology & translational science2026-11-18

The Ergogenic Effect of Caffeine in Rodents: A Systematic Review and Meta-Analysis, with a Narrative Synthesis of Adenosine A2A Receptor Mechanisms.

de Souza Santos Naiara N, Fabro Izabel Feltrin IF, Carminati Dos Santos Beatriz B, Pereira Débora Maria Russiano DMR et al.

Caffeine is a widely consumed ergogenic aid and a nonselective antagonist of adenosine receptors, including the facilitatory A2A subtype (A2AR), yet the magnitude of its performance-enhancing effect in rodents has not been formally quantified. We conducted a systematic review and meta-analysis of rodent studies administering caffeine before exercise, with risk of bias assessed using the SYRCLE tool (PROSPERO CRD420250653223). Fourteen studies met the eligibility criteria. Six studies of a single systemic dose preceding an aerobic task, comprising 71 animals were pooled using a restricted maximum likelihood random-effects model with a Hartung-Knapp interval, yielding a large ergogenic estimate with wide uncertainty (Hedges' g = +1.31; 95% CI + 0.29 to +2.32; I2 = 71%). Prespecified rules, applied independently of the observed effects, precluded pooling of the two anaerobic studies, which measured different performance constructs, and of the three chronic-exposure studies, whose dosing regimens and exercise modalities were not comparable; these are reported descriptively, as are the intracerebral administration experiments. Risk of bias was frequently unclear or high in the randomization and blinding domains. Receptor-level evidence is reported separately as a narrative synthesis, because the search was not constructed to retrieve mechanistic studies: the ergogenic response was abolished in global and forebrain A2AR-knockout mice and reproduced by the selective antagonist SCH 58261, whereas A2AR agonism with NECA was ergolytic and reversed by caffeine, and deletion of CD73, which depletes the extracellular adenosine pool preferentially supplying A2AR, recapitulated the ergogenic phenotype. The rodent evidence provides preclinical support for A2AR involvement in exercise-induced fatigue on an evidence base too small and too heterogeneous to support therapeutic or performance translation.

PMID 43048230
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Adenosine